Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives

口服避孕药预防卵巢癌的机制

• 批准号: 8571076
• 负责人: CELESTE Leigh PEARCE
• 金额: $ 21.68万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-17 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8571076
• 关键词: Accounting; Address; BRCA1 gene; Bilateral; Cancer Etiology; Cell Proliferation; Cells; Cessation of life; Chemoprevention; Clear Cell; Contraceptive Usage; Data; Developed Countries; Development; Diagnosis; Disease; Dose; Drug Formulations; Ensure; Environment; Epidemiologic Studies; Epithelial cyst; Epithelial ovarian cancer; Epithelium; Estrogen Therapy; Exposure to; Foundations; Goals; Health; Hormonal; Lesion; Luteal Phase; Malignant Neoplasms; Malignant neoplasm of ovary; Mammalian Oviducts; Menopause; Menstrual cycle; Meta-Analysis; Metaplastic; Mucinous; Mutation; Neoplastic Cell Transformation; Oral Contraceptives; Ovarian; Ovary; Ovulation; Pattern; Population; Progesterone; Progestins; Proliferating; Regimen; Reporting; Risk; Salpingo-Oophorectomy; Secondary to; Serous; Site; Source; Specimen; Staging; Surface; Uncertainty; Woman; base; cancer risk; cell type; fimbria; high risk; improved; mutation carrier; ovarian cancer prevention; proliferative phase Menstrual cycle; protective effect; screening; tool

DESCRIPTION (provided by applicant): Five-year survival for invasive epithelial ovarian cancer (ovarian cancer) is less than 50% because most women are diagnosed at an advanced stage. However, there is an effective chemoprevention strategy. Meta-analysis of epidemiological studies shows an approximately 40% reduction in risk of ovarian cancer with 5 years of oral contraceptive (OC) use. The protective effect increases significantly with duration of OC use and continues for at least 25 years after use of OCs is stopped. The mechanism(s) underlying this protective effect are not understood. One hypothesis is that protection is achieved by blocking ovulation, but growing evidence suggests that it may be related to promoting a favorable progestagenic environment. OC use would protect if the hormonal exposure while on OCs was less stimulatory to the possibly different types of cells of origin of ovarian cancer than the hormonal exposure in normal ovulatory cycles. Exposure to progestins is higher while on OCs than in normal cycling and this could explain the protective effect. We propose that a major source of the protection from OC use is due to their significantly reducing cell proliferation in the fallopian tube fimbriae (FTF) and in ovarian cortical inclusion cysts (CICs), two likely cells of origin for ovarian cancer. Proliferating cell populations are more susceptible to carcinogenic effects with the rise in cancer risk with cell proliferation being secondary to increased chances of mutation and progression. FTF proliferation has been reported to be almost confined to the follicular phase of the menstrual cycle with virtually no proliferation within a few days after ovulation and our preliminary data show the same pattern - OCs could thus protect against ovarian cancers arising in the FTF by mimicking the luteal phase of the cycle when progesterone exposure is high. Whether such changes occur in CICs is not known. Cell proliferation within different types of CICs during the menstrual cycle has not been studied. The effect of OCs on proliferation within the FTF and CICs has also not been studied. We are proposing to determine the effect of a 'traditional' high progestin dose OC on cell proliferation in the FTF and CICs in women undergoing a risk-reducing bilateral salpingo-oophorectomy (RR-BSO), and to compare these proliferation rates to the rates during the normal menstrual cycle of women also undergoing an RR-BSO. The results of this study will provide crucial information regarding the relationship between OC use and protection against ovarian cancer. It will lay the foundation for further studies examining the effects of lower progestin dose OCs and OCs with newer progestin formulations. Our long-term goal in studying the mechanism of OC protection is to determine whether it is likely that the protection against ovarian cancer afforded by OCs will be lost with alterations in OC formulation in terms of dose or type of progestin used, and, if possible, to guide development of OC formations to improve further on the protection afforded by OCs.

描述(申请人提供)：浸润性上皮性卵巢癌(卵巢癌)的五年存活率不到50%，因为大多数女性都是在晚期确诊的。然而，有一种有效的化学预防策略。流行病学研究的荟萃分析显示，口服避孕药(OC)使用5年，患卵巢癌的风险降低约40%。这种保护作用随着OC使用时间的延长而显著增加，并在停止使用OCS后至少持续25年。这种保护作用背后的机制(S)尚不清楚。一种假设是通过阻止排卵来实现保护作用，但越来越多的证据表明，这可能与促进有利的促孕激素环境有关。如果在OCS期间的激素暴露比正常排卵周期中的激素暴露对可能不同类型的卵巢癌起源细胞的刺激作用更小，则OC的使用将起到保护作用。在OCS上接触孕激素的次数比正常骑行时高，这可以解释这种保护作用。我们认为，使用OC的保护作用的一个主要来源是由于OC显著降低了输卵管伞状细胞(FTF)和卵巢皮质包涵体囊(CICs)中的细胞增殖，这两种细胞可能是卵巢癌的起源细胞。随着癌症风险的增加，增殖细胞群体更容易受到致癌作用的影响，细胞增殖是次要的，突变和进展的机会增加。据报道，FTF的增殖几乎局限于月经周期的卵泡期，在排卵后的几天内几乎没有增殖，我们的初步数据也显示了同样的模式-OCS因此可以通过模仿黄体期的黄体期来预防FTF中发生的卵巢癌。目前尚不清楚这种变化是否发生在CIC中。月经周期中不同类型的CICs中的细胞增殖尚未被研究。OCS对FTF和CICs内增殖的影响也尚未被研究。我们建议在降低风险的双侧输卵管卵巢切除术(RR-BSO)中确定“传统的”高剂量孕激素对FTF和CICS中细胞增殖的影响，并将这些增殖率与同样接受RR-BSO的女性在正常月经周期中的增殖率进行比较。这项研究的结果将提供有关OC使用和预防卵巢癌之间关系的关键信息。这将为进一步研究较低剂量的孕激素OCS和OCS与较新的孕激素制剂的效果奠定基础。我们研究卵巢癌保护机制的长远目标，是要确定卵巢癌组织对卵巢癌的保护作用，会否因为改变所用孕激素的剂量或种类而丧失，并在可能的情况下，引导卵巢组织的形成，以进一步改善组织细胞对卵巢癌的保护。